Pharmaceutical company SynCore Biotechnology Co Ltd (杏國新藥) yesterday said that it plans to begin a phase III clinical trial of its new pancreatic cancer drug SB05PC in China, after gaining the approval of the Chinese regulator last month.
As the company has completed a phase II trial for SB05PC in the US, the Chinese National Medical Products Administration (NMPA) approved the phase III trial, a company official surnamed Liang (梁) told the Taipei Times by telephone yesterday.
The company is still looking for hospitals with which to cooperate and finalizing the number of patients, but expects to complete the trial by the fourth quarter of 2021, Liang said.
The drug’s potential in China would be huge, as China has the most patients with pancreatic cancer in the world and the NMPA has not selected a medication to be the first-line treatment, unlike its European counterparts, Liang added.
A first-line treatment is one approved by the regulators as the best treatment. Doctors must adopt it first and cannot easily transfer to other treatments unless the first-line treatment does not work or causes serious side effects.
SynCore has applied for SB05PC to be a first-line treatment in China, Liang said.
The number of patients diagnosed with pancreatic cancer in China totaled 116,300 last year and a total of 110,400 patients died, he said citing WHO data.
Meanwhile, the company’s global phase III clinical trial in seven other nations — Taiwan, the US, France, Hungary, South Korea, Russia and Israel — is progressing smoothly, he said.
In those seven markets, the drug would be used as a second-line treatment in combination with gemcitabine for those who have exhausted commonly prescribed first-line chemotherapy treatments.
The company is to conduct interim analysis of the trial at the end of this year, Liang said.
Based on the results of the phase II trial, the company said it is confident that the phase III trial will meet its primary efficacy endpoint and improve the rates of survival of enrolled patients.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by